Recently, several multigene assays have been developed to improve patient selection among women with early stage, hormone positive and HER2 negative, breast cancer that have a higher risk for disease recurrence and may benefit from adding chemotherapy to adjuvant hormone therapy [34, 35]. This evidence concerns the gene ERBB2 and breast cancer.